following an abbreviated submission
atomoxetine oral solution (Strattera®) is accepted for restricted use within NHS Scotland.
Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
SMC restriction: to use in patients who are unable to swallow capsules.
Atomoxetine oral solution demonstrated bioequivalence to atomoxetine capsules. The availability of the oral solution will provide a formulation acceptable to patients who cannot swallow capsules. Any overall budget impact is likely to be small.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- atomoxetine (Strattera)
- SMC ID:
- 1107/15
- Indication:
- treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 07 December 2015